Jerome H. Kim, M.D., is the Director General of the International Vaccine Institute (IVI). He served as the Principal Deputy and Chief of the Laboratory of Molecular Virology and Pathogenesis at MHRP, in addition to being the Project Manager for the HIV Vaccines and Advanced Concepts Evaluation Project Management Offices, U.S. Army Medical Material Development Activity U.S.A., Dr. Kim was a Professor within the Division of Infectious Diseases of the Department of Medicine at the Uniformed Services University of the Health Sciences. From 2004 – 2009 he led the Army’s Phase III HIV vaccine trial (RV144), the first demonstration that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates of protection and sequence changes in breakthrough HIV infections after vaccination. Dr. Kim graduated from the Yale University School of Medicine in 1984 and completed his training in Internal Medicine and fellowship in Infectious Diseases at Duke University Medical Center. In 2013 he received the John Maher Award for Research Excellence from the Department of Medicine, Uniformed Services University of the Health Sciences. Throughout his career to date, Dr. Kim has authored over 200 publications.

Dr. Lynch is the Deputy Director General of Development & Delivery. Prior to IVI, she served 29 years in the U.S. Army. Dr. Lynch first served as Director of the Division of Viral Diseases at the Walter Reed Army Institute of Research, during which time significant studies were conducted for Japanese encephalitis, adenovirus and dengue vaccines. She was appointed Director of the Military Infectious Disease Research Program at Fort Detrick, Maryland; a product development program targeting vaccines against malaria, dengue and enteric pathogens, as well as new anti-parasitic drugs and infectious disease diagnostics for resource-limited settings. She later became the Science Director for the Armed Forces Research Institute of Medical Sciences in Bangkok, Thailand where she was responsible for activities spanning eight countries in South-East Asia which included biosurveillance, basic science, pre-clinical studies, and human clinical trials. Dr. Lynch received her M.D. from Columbia University and completed a Pediatric Residency and Infectious Disease fellowship at the Walter Reed Army Medical Center.

Mr. Francois Belin is the Deputy Director General, Chief Operating Officer of IVI. He is a finance professional with an extensive global pharmaceuticals and cross-cultural background, having served in increasingly senior finance positions over the course of the last 23 years, first in Pfizer, then Sanofi. Within Pfizer he held positions as CFO for Central & Eastern Europe (Karlsruhe), Canada (Montreal), Japan (Tokyo), and Emerging Markets & Asia Regional CFO (New York). Upon joining Sanofi, he served as Group CFO China/Asia in Shanghai, before taking the role of Vice President, Head of Finance Transformation in the Sanofi HQ in Paris until joining IVI. Mr. Belin was born in Germany, lived in Italy, and holds an M.Sc. in Management from ESSEC Business School (France).

Dr. Han is the Deputy Director General of IVI’s Government & Global Affairs Unit. This unit oversees engagement with the Korean government and other global stakeholders. Dr. Han has more than 30 years’ experience as a senior official in the Korean government in the areas of economic policy and budgeting. Among his positions were: Director General of the Technology & Safety Policy Bureau, Ministry of Construction and Transportation; Director General of the Policy Analysis Bureau, National Economic Advisory Council; and Chief Executive Auditor of the Korea Credit Guarantee Fund. He was also an Adjunct Professor at Seoul National University of Science and Technology. Dr. Han has a Ph.D. in economics from the University of Hawaii; a Master of Science in management science from the Korea Advanced Institute of Science and Technology (KAIST); and a Master of Public Administration and a Bachelor of Arts in economics from Seoul National University. He is a Certified Internal Auditor of the Institute of Internal Auditors, U.S.A.

Dr. Song is the Head of IVI’s Clinical Research Lab Department. He has had a longstanding interest in public health and threats to health of developing country populations. In the first years of his career, he focused on viral diseases, particularly HIV, HBV and HCV. Most recently, as the Head of the Clinical Research Lab Department at IVI, he broadened the scope of his studies to include Norovirus and MERS-CoV vaccine development.
Before joining IVI as a research scientist in 2004, Dr. Song served as an IVI postdoctoral fellow in 2001 at Prof. Myron Levine’s Center for Vaccine Development (CVD) at the University of Maryland School of Medicine in Baltimore, U.S.A. During this period, he focused on the development of new-generation measles vaccines using naked DNA, attenuated Shigella, and Salmonella. Dr. Song has also actively served on steering committees of many academic societies including the Korea Association of Immunologists and the Korean Vaccine Society. After two years of service as a Review Board member of the Korea National Research Foundation (Immunology in Medical Science), he has been working as a Program Manager of the state-run Korea Health Industry Development Institute (KHIDI) since 2015. Dr. Song received his B.Sc. degree from Seoul National University, and his M.Sc. and Ph.D. degrees from Pohang University of Science and Technology (POSTECH).